Next Science shares defy ASX market slump to surge 8%

Next Science shares are set to finish Thursday's trading session on a high note.

| More on:
Rising arrow on a blue graph symbolising a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Next Science shares leap 8.54% to 89 cents during mid-afternoon trade 
  • The company announced a multi-year distribution agreement with Oraderm Pharmaceuticals 
  • Under the deal, BlastX will be sold and marketed across Australia and New Zealand from the second half of 2022 

The Next Science Ltd (ASX: NXS) share price is roaring higher today despite the ASX being deep in the red.

At the time of writing, the medical technology company's shares are fetching at 89 cents a pop, up 8.54%.

In contrast, the All Ordinaries Index (ASX: XAO) is trading at 7,318.5 points, down 1.46%.

Next Science expands 'commercial footprint'

Investors are buying up the Next Science share price after the company revealed a positive update to the market.

In its release, Next Science advised it has signed a multi-year distribution agreement with Oraderm Pharmaceuticals to sell BlastX.

Located in Cremone, Victoria, Oraderm Pharmaceuticals is a medical sales joint venture between Douglas Pharmaceuticals and Arrotex Pharmaceuticals.

Under the deal, Oraderm will have exclusive rights across Australia and New Zealand for the sale and marketing of BlastX. However, this will be a dual Next ScieUnce/Oraderm labelled version. 

Next Science is expected to receive a portion of revenues based on an agreed unit price and a minimum quantity per order.

The agreement will run for a period of five years but can be extended for another three years.

Oraderm's initial focus in Australia will be hospitals, nursing homes, dermatologists and over-the-counter pharmacy sales.

In New Zealand, Oraderm will concentrate on wound care in hospitals and other clinical settings accommodating varied distribution solutions.

Next Science is scheduled to deliver training to the distributor's sales force teams in late June. Commercial sales in Australia and New Zealand are expected to commence during the second half of 2022.

Next Science managing director, Judith Mitchell commented:

We are delighted to expand our commercial footprint for BlastX in Australia and New Zealand through Oraderm.

Oraderm is a well-known brand within the healthcare industry with a track record of success in bringing new products to market. This partnership enhances our ability to offer our proven wound care product to healthcare professionals and patients in Australia and New Zealand as we continue to pursue our mission to heal patients and save lives worldwide by reducing the impacts of biofilms on human health.

Next Science share price summary

Over the past 12 months, the Next Science share price has continued to tread lower to post a loss of 46%.

It's worth noting that the company's share price hit a fresh 52-week low of 79.5 cents in late April.

Based on valuation grounds, Next Science presides a market capitalisation of roughly $177.74 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Next Science Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »